Squamous cell carcinoma antigen

Abstract

on behalf of the Mount Vernon Colorectal Cancer Network BACKGROUND: The objective of this retrospective study was to investigate the predictive value of pretreatment serum squamous cell carcinoma antigen (SCCAg) levels in 174 patients with squamous cell carcinoma of the anus who received concurrent chemoradiation between 1997 and 2010. METHODS: Pretreatment serum SCCAg measurements in patients with histologically diagnosed squamous cell carcinoma of the anal canal and margin who received chemoradiation were compared with clinical tumor classification and lymph node status for prognostic/predictive ability, including 1) tumor response after the completion of chemoradiation treatment, 2) disease recurrence, and 3) overall survival. Clinical measurements and scores were compared using Spearman rank tests, and survival was assessed in both univariate and multivariate survival analyses. RESULTS: The median pretreatment levels of SCCAg according to clinical tumor classification and clinical lymph node status were 0.8 lg/L in T1 tumors, 1.90 lg/L in T2 tumors, 2.5 lg/L in T3 tumors, 3.8 lg/L in T4 tumors, 1.35 lg/L in patients with N0 status, and 3.05 lg/L in patients with N01 status (correlation coefficient: T-classification, 0.43; lymph node status, 0.38; both P <.00001). Of the patients who had normal SCCAg levels, 95% achieved a complete response after initial treatment; and, of those who had elevated SCCAg levels, 86% achieved a complete response (P 5.05). Overall survival (hazard ratio, 2.5; P 5.007) and disease-free survival (hazard ratio, 2.2; P 5.058) were worse for those who had elevated pretreatment serum SCCAg concentrations. CONCLUSIONS: Pretreatment SCCAg levels in patients with squamous cell carcinoma of the anal canal and margin were correlated with clinical tumor classification and clinical lymph node status. Elevated levels of SCCAg were associated with a reduced chance of achieving a complete response and an increased chance of recurrence and death. The authors recommend further studies to determine the prognostic value of SCCAg in anal squamous cell carcinoma and suggest the potential use of SCCAg as a stratification factor in future trials.

Biomarkers in anal cancer: from biological understanding to stratified treatment

“…With respect to anal cancer, levels at baseline have been reported to have prognostic value. Specifically 49% of 174 patients demonstrated raised plasma SCCA (Williams et al , 2013) at presentation, correlating with reduced complete response to treatment and reduced disease-free and OS. More recently there has been interest in SCCA in follow up where one small study of 24 patients was not consistent with respect to baseline prognosis, but during follow up, 2 patients demonstrated a rise of SCCA, one of whom developed recurrence and metastatic disease (Henkenberens et al , 2016).…”

Nanodetection of Head and Neck Cancer on Titanium Oxide Sensing Surface

“…Serologic tumour markers have been used to diagnose and manage the follow-up treatment of head and neck cancer. The squamous cell releases a predominant squamous cell carcinoma antigen (SCC-Ag), its presence elevated in cancer patients and SCC-Ag has shown to be a promising tumour marker with squamous cell-related cancers such as gynaecologic, lung, oesophageal and anal cancers [3,4]. Considering head and neck cancer, higher levels of SCC-Ag have been associated with disease metastasis, recurrence and mortality as attested in different studies with cancer patients [5][6][7].…”

Predictive value of preoperative serum squamous cell carcinoma antigen (SCC–Ag) level on tumor recurrence in cervical squamous cell carcinoma patients treated with radical surgery: A single-institution study

“…SCC-Ag is a serological marker of tumor-associated antigen and is derived from the tissues of squamous cell carcinoma [6]. Previous studies reported that serum SCC-Ag level was related to the tumor stage, tumor size, depth of invasion, parametrial invasion, and lymph node metastasis in patients with cervical squamous cell carcinoma, and was an independent indicator of patient's response to treatment [7e10].…”